康莱特注射液联合NP方案治疗晚期非小细胞肺癌临床疗效观察

Therapeutic effect of Kanglaite injection combined with chemotherapy on advanced non-small-cell lung cancer

目的观察康莱特注射液(KLT)联合化疗对晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC)的治疗效果。方法试验组:采用异长春花碱(NVB)+顺铂(DDP)方案化疗2个周期,同时加用康莱特注射液200ml/d静脉滴注,21d为1个疗程,共2个疗程。对照组单用NVB+DDP。结果两组有效率分别为59.0%(23/39)和36.6%(15/41)P<0.05,差异显著;试验组骨髓抑制发生率为23.1%(9/39),而对照为43.9%(18/41),P<0.05,差异显著;试验组消化道不良反应发生率为12.8%(5/39),对照组为24.4%(10/41),P<0.05,差异显著;试验组治疗前后KPS评分及体质量评分明显高于对照组,P<0.01,差异非常显著。结论康莱特联合NP方案化疗可提高化疗的疗效,减轻化疗的不良反应,使患者的生存质量得到改善。

Objective To observe the therapeutic effect of Kanglaite injection combined with chemotherapy on advanced non-small-cell lung cancer.Methods 80 patients with non-small-cell lung cancer were randomly divided into two groups. 39 patients in trial group were treated by chemotherapy of NVP ＋ DDP regimen combined with Kanglaite injection 200 ml/d for 42 days;41 patients in control group were treated by chemotherapy of NVB ＋ DDP only. Results The effective rates were 59.0%（23/29） in trial group and 36.6% （15/41） in control group, there was a significant difference between two groups （ P 〈 0.05）. The bone marrow suppression and digestive system side-effects in trial group were significantly lower than those in control group （ P 〈 0.05）. KPS and body weight score in trial group were significantly higher than those in control group （ P 〈 0.01）. Conclusions Kanglaite injection combined with chemotherapy could increase effective rate, reduce side-effects of chemotherapy and improve life quality.